New agents promote neuroprotection in Parkinson's disease models

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 410-418

  Santos, Claudia Maria Miranda ^a  

^a Department of Neurology   (Brazil)

Author keywords

Alpha synuclein; Dopamine; Gene therapy; Neuroprotection; Parkin; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 9 METHYL BETA CARBOLINE; ACETYLCYSTEINE; BCG VACCINE; CANNABINOID; CURCUMIN; DOXYCYCLINE; FISETIN; FLUOXETINE; GLATIRAMER; LEVODOPA; MANEB; MELATONIN; NARINGENIN; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PARAQUAT; PAROXETINE; PHENOL DERIVATIVE; QUERCETIN; RECOMBINANT ERYTHROPOIETIN; RESERPINE; ROTENONE; ROTTLERIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TRICHLOROETHYLENE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZONISAMIDE;

GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOREACTIVITY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; TRANSPLANTATION; VITAMIN D DEFICIENCY;

EID: 84862509879     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792820     Document Type: Review

References (58)

1. Feng, L.R.; Maguire-Zeiss, K.A. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs, 2010, 24(3), 177-192.
2. Leegwater-Kim, J.; Bortan, E. The role of rasagiline in the treatment of Parkinson's disease. Clin. Interv. Aging, 2010, 5, 149-156.
3. Olanow, C.W.; Stern, M.B.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology, 2009, 72(21 Suppl 4), S1-S136.
4. Brotchie, J.; Fitzer-Attas, C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology, 2009, 72(7 Suppl), S32-S38.
5. Tolosa, E.; Gaig, C.; Santamaría, J.; Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology, 2009, 72(7 Suppl), S12-S20.
6. Hickey, P.; Stacy, M. Available and emerging treatments for Parkinson's disease: a review. Drug Des. Devel. Ther., 2011, 5, 241-254.
7. Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys., 2011, 508(1), 1-12.
8. Haavik, J.; Toska, K. Tyrosine hydroxylase and Parkinson's disease. Mol. Neurobiol., 1998, 16(3), 285-309.
9. Nakashima, A.; Hayashi, N.; Kaneko, Y.S.; Mori, K.; Sabban, E.L.; Nagatsu, T.; Ota, A. Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines. J. Neural Transm., 2009, 116(11), 1355-1362.
10. Hauser, R.A.; Zesiewicz, T.A. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology, 2006, 66(10 Suppl 4), S58-S68.
11. Boll, M.C.; Alcaraz-Zubeldia, M.; Rios, C. Medical management of Parkinson's disease: focus on neuroprotection. Curr. Neuropharmacol., 2011, 9(2), 350-359.
12. Ahlskog, J.E.; Uitti, R.J. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology, 2010, 74(14), 1143-1148.
13. Berman, A.E.; Chan, W.Y.; Brennan, A.M.; Reyes, R.C.; Adler, B.L.; Suh, S.W.; Kauppinen, T.M.; Edling, Y.; Swanson, R.A. Nacetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse. Ann. Neurol., 2011, 69(3), 509-520.
14. Antony, P.M.; Diederich, N.J.; Balling, R. Parkinson's disease mouse models in translational research. Mamm. Genome, 2011, 22(7-8), 401-419.
15. Sotnikova, T.D.; Caron, M.G.; Gainetdinov, R.R. DDD mice, a novel acute mouse model of Parkinson's disease. Neurology, 2006, 67(7 Suppl 2), S12-S17.
16. Anderson, D.W.; Bradbury, K.A.; Schneider, J.S. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur. J. Neurosci., 2006, 24(11), 3174-3182.
17. Alerte, T.N.; Akinfolarin, A.A.; Friedrich, E.E.; Mader, S.A.; Hong, C.S.; Perez, R.G. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci. Lett., 2008, 435(1), 24-29.
18. Peng, X.; Tehranian, R.; Dietrich, P.; Stefanis, L.; Perez, R.G. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell. Sci., 2005, 118, 3523-3530.
19. Dawson, T.M.; Ko, H.S.; Dawson, V.L. Genetic animal models of Parkinson's disease. Neuron, 2010, 66(5), 646-661.
20. Kanaan, N.M.; Collier, T.J.; Marchionini, D.M.; McGuire, S.O.; Fleming, M.F.; Sortwell, C.E. Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease. Brain Res., 2006, 1068(1), 221-229.
21. Xue, Y.Q.; Zhao, L.R.; Guo, W.P.; Duan, W.M. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience, 2007, 146(3), 1245-1258.
22. Yasuhara, T.; Matsukawa, N.; Hara, K.; Yu, G.; Xu, L.; Maki, M.; Kim, S.U.; Borlongan, C.V. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J. Neurosci., 2006, 26(48), 12497-12511.
23. Kong, X.Y.; Cai, Z.; Pan, L.; Zhang, L.; Shu, J.; Dong, Y.L.; Yang, N.; Li, Q.; Huang, X.J.; Zuo, P.P. Transplantation of human amniotic cells exerts neuroprotection in MPTP-induced Parkinson disease mice. Brain Res., 2008, 1205, 108-115.
24. Zbarsky, V.; Datla, K.P.; Parkar, S.; Rai, D.K.; Aruoma, O.I.; Dexter, D.T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic. Res., 2005, 39(10), 1119-1125.
25. Cho, Y.; Son, H.J.; Kim, E.M.; Choi, J.H.; Kim, S.T.; Ji, I.J.; Choi, D.H.; Joh, T.H.; Kim, Y.S.; Hwang, O. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox. Res., 2009, 16(4), 361-371.
26. Mythri, R.B.; Veena, J.; Harish, G.; Shankaranarayanarao, B.S.; Srinivas Bharath, M.M. Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease. Br. J. Nutr., 2011, 106(1), 63-72.
27. Huh, S.H.; Chung, Y.C.; Piao, Y.; Jin, M.Y.; Son, H.J.; Yoon, N.S.; Hong, J.Y.; Pak, Y.K.; Kim, Y.S.; Hong, J.K.; Hwang, O.; Jin, B.K. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J. Immunol., 2011, 187(2), 960-969.
28. Wernicke, C.; Hellmann, J.; Zieba, B.; Kuter, K.; Ossowska, K.; Frenzel, M.; Dencher, N.A.; Rommelspacher, H. 9-Methyl-betacarboline has restorative effects in an animal model of Parkinson's disease. Pharmacol. Rep., 2010, 62(1), 35-53.
29. Yasuhara, T.; Shingo, T.; Kobayashi, K.; Takeuchi, A.; Yano, A.; Muraoka, K.; Matsui, T.; Miyoshi, Y.; Hamada, H.; Date, I. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur. J. Neurosci., 2004, 19(6), 1494-1504.
30. Junqiang, Y.; Yunqi, X.; Cansheng, Z.; Limin, Z.; Aimin, W.; Yu, Y.; Zhaojun, X.; Chao, D.; Xu-Feng, H.; Midori, A. Y.; Yuan-Guo, Y.; Weihai, Y.; Qing, W. Simvastatin Prevents Dopaminergic Neurodegeneration in Experimental Parkinsonian Models: The Association with Anti-Inflammatory Responses. PLoS One, 2011, 6(6), e20945.
31. Murata, M. The discovery of an antiparkinsonian drug, zonisamide. Rinsho Shinkeigaku, 2010, 11, 780-782.
32. Van Vliet, S.A.; Blezer, E.L.; Jongsma, M.J.; Vanwersch, R.A.; Olivier, B.; Philippens, I.H. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res., 2008, 1189, 219-228.
33. Ma, J.; Shaw, V.E.; Mitrofanis, J. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat. Disord., 2009, 15(4), 307-314.
34. Sharma, R.; McMillan, C.R.; Tenn, C.C.; Niles, L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res., 2006, 1068(1), 230-236.
35. Clark, J.; Clore, E.L.; Zheng, K.; Adame, A.; Masliah, E.; Simon, D.K. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One, 2010, 5(8), e12333.
36. Lastres-Becker, I.; Molina-Holgado, F.; Ramos, J.A.; Mechoulam, R.; Fernández-Ruiz, J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis., 2005, 19(1-2), 96-107.
37. Zhang, D.; Anantharam, V.; Kanthasamy, A.; Kanthasamy, A.G. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J. Pharmacol. Exp. Ther., 2007, 322(3), 913-922.
38. Chung, Y.C.; Kim, S.R.; Park, J.Y.; Chung, E.S.; Park, K.W.; Won, S.Y.; Bok, E.; Jin, M.; Park, E.S.; Yoon, S.H.; Ko, H.W.; Kim, Y.S.; Jin, B.K. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology, 2011, 60(6), 963-974.
39. Chung, Y.C.; Kim, S.R.; Jin, B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J. Immunol., 2010, 185(2), 1230-1237.
40. Yang, L.; Calingasan, N.Y.; Wille, E.J.; Cormier, K.; Smith, K.; Ferrante, R.J.; Beal, M.F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem., 2009, 109(5), 1427-1439.
41. Yong, J.; Lacan, G.; Dang, H.; Hsieh, T.; Middleton, B.; Wasserfall, C.; Tian, J.; Melega, W.P.; Kaufman, D.L. BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease. PLoS One, 2011, 6(1), e16610.
42. Annweiler, C.; Beauchet, O. Vitamin d-mentia: randomized clinical trials should be the next step. Neuroepidemiology, 2011, 37(3-4), 249-258.
43. Miranda-Santos, C.M.; Araujo, E.A.S.; Thome, L.F.; Lima, P.M.V. In: Modelo de projeto multicêntrico em esclerose múltipla (Portuguese Edition); CreateSpace, 2011; Vol. 1, pp. 33-34.
44. Ascherio, A.; Munger, K.L.; Simon, K.C. Vitamin D and multiple sclerosis. Lancet Neurol., 2010, 9(6), 599-612.
45. Knekt, P.; Kilkkinen, A.; Rissanen, H.; Marniemi, J.; Sääksjärvi, K.; Heliövaara, M. Serum vitamin D and the risk of Parkinson disease. Arch. Neurol., 2010, 67(7), 808-811.
46. Shaw, V.E.; Spana, S.; Ashkan, K.; Benabid, A.L.; Stone, J.; Baker, G.E.; Mitrofanis, J. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J. Comp. Neurol., 2010, 518(1), 25-40.
47. Ceravolo, R.; Nuti, A.; Piccinni, A.; Dell'Agnello, G.; Bellini, G.; Gambaccini, G.; Dell'Osso, L.; Murri, L.; Bonuccelli, U. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology, 2000, 55(8), 1216-1218.
48. Corti, O.; Sánchez-Capelo, A.; Colin, P.; Hanoun, N.; Hamon, M.; Mallet, J. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 1999, 96(21), 2120-2125.
49. Barber-Singh, J.; Seo, B.B.; Nakamaru-Ogiso, E.; Lau, Y.S.; Matsuno-Yagi, A.; Yagi, T. Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res., 2009, 12(4), 259-267.
50. Maguire-Zeiss, K.; Horovitz, K.; Ankoudinova, I.; Guschin, D.; Hadaczek, P.; Federoff, H.J.; Bankiewicz, K.; Forsayeth, J. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol. Ther., 2008, 16(8), 1392-1399.
51. Brizard, M.; Carcenac, C.; Bemelmans, A.P.; Feuerstein, C.; Mallet, J.; Savasta, M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol. Dis., 2006, 21(1), 90-101.
52. Eberling, J.L.; Jagust, W.J.; Christine, C.W.; Starr, P.; Larson, P.; Bankiewicz, K.S.; Aminoff, M.J. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology, 2008, 70(21), 1980-1983.
53. Lo-Bianco, C.; Schneider, B.L.; Bauer, M.; Sajadi, A.; Brice, A.; Iwatsubo, T.; Aebischer, P. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2004, 101(50), 17510-17515.
54. Carlsson, T.; Winkler, C.; Burger, C.; Muzyczka, N.; Mandel, R.J.; Cenci, A.; Björklund, A.; Kirik, D. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain, 2005, 128(Pt 3), 559-569.
55. Wang, W.J.; Sun, M.S.; Yan, M.; Xie, T.H.; Zhang, G.M.; Li, H.J. Recombinant adenovirus-mediated expression of tyrosine hydroxylase in 293 cells and activity assay of the expressed protein in vitro by capillary electrophoresis. Nan. Fang Yi Ke Da Xue Xue Bao, 2010, 30(4), 681-685.
56. Jarraya, B.; Boulet, S.; Ralph, G.S.; Jan, C.; Bonvento, G.; Azzouz, M.; Miskin, J.E.; Shin, M.; Delzescaux, T.; Drouot, X.; Hérard, A.S.; Day, D.M.; Brouillet, E.; Kingsman, S.M.; Hantraye, P.; Mitrophanous, K.A.; Mazarakis, N.D.; Palfi, S. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med., 2009, 1(2), 2-4.
57. Björklund, T.; Carlsson, T.; Cederfjäll, E.A.; Carta, M.; Kirik, D. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Neurosci. Lett., 2008, 435(1), 24-29.
58. Zhuo, M.; Xu, D.H.; Cao, L.; Xu, L.F.; Yu, F.R.; Zheng, Z.C.; Liu, X.Y. Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 2003, 35(12), 1066-1071.